Adjusted clinical outcomes by degree of HLA-A, -B, -C, and -DRB1 matching
| . | N . | RR or OR . | 95% CI . | P . |
|---|---|---|---|---|
| Mortality* | .002 | |||
| 8/8 match | 372 | 1.00 | ¶ | ¶ |
| 1 MM | 191 | 1.29 | 0.97-1.72 | .079 |
| 2 MM, allele or antigen | 100 | 1.82 | 1.30-2.55 | .0004 |
| Acute GVHD II-IV† | .74 | |||
| 8/8 match | 384 | 1.00 | ¶ | ¶ |
| 1 MM | 190 | 0.99 | 0.75-1.30 | .92 |
| 2 MM, allele or antigen | 89 | 1.14 | 0.79-1.64 | .47 |
| Acute GVHD III-IV‡ | .60 | |||
| 8/8 match | 384 | 1.00 | ¶ | ¶ |
| 1 MM | 190 | 1.14 | 0.79-1.62 | .48 |
| 2 MM, allele or antigen | 89 | 1.25 | 0.78-1.99 | .36 |
| Chronic GVHD§ | .40 | |||
| 8/8 match | 368 | 1.00 | ¶ | ¶ |
| 1 antigen MM | 182 | 0.85 | 0.59-1.23 | .39 |
| 2 MM, allele or antigen | 89 | 1.24 | 0.75-2.04 | .41 |
| Graft failure‖ | .0001 | |||
| 8/8 match | 386 | 1.00 | ¶ | ¶ |
| 1 antigen MM | 188 | 2.81 | 1.74-4.54 | < .0001 |
| 2 MM, allele or antigen | 89 | 2.22 | 1.26-3.97 | .006 |
| . | N . | RR or OR . | 95% CI . | P . |
|---|---|---|---|---|
| Mortality* | .002 | |||
| 8/8 match | 372 | 1.00 | ¶ | ¶ |
| 1 MM | 191 | 1.29 | 0.97-1.72 | .079 |
| 2 MM, allele or antigen | 100 | 1.82 | 1.30-2.55 | .0004 |
| Acute GVHD II-IV† | .74 | |||
| 8/8 match | 384 | 1.00 | ¶ | ¶ |
| 1 MM | 190 | 0.99 | 0.75-1.30 | .92 |
| 2 MM, allele or antigen | 89 | 1.14 | 0.79-1.64 | .47 |
| Acute GVHD III-IV‡ | .60 | |||
| 8/8 match | 384 | 1.00 | ¶ | ¶ |
| 1 MM | 190 | 1.14 | 0.79-1.62 | .48 |
| 2 MM, allele or antigen | 89 | 1.25 | 0.78-1.99 | .36 |
| Chronic GVHD§ | .40 | |||
| 8/8 match | 368 | 1.00 | ¶ | ¶ |
| 1 antigen MM | 182 | 0.85 | 0.59-1.23 | .39 |
| 2 MM, allele or antigen | 89 | 1.24 | 0.75-2.04 | .41 |
| Graft failure‖ | .0001 | |||
| 8/8 match | 386 | 1.00 | ¶ | ¶ |
| 1 antigen MM | 188 | 2.81 | 1.74-4.54 | < .0001 |
| 2 MM, allele or antigen | 89 | 2.22 | 1.26-3.97 | .006 |
N indicates the number of patient-donor pairs; RR, relative risk; OR, odds ratio; CI, confidence interval; MM, mismatch; GVHD, graft-versus-host disease; and ATG, antithymocyte globulin.
Mortality was also adjusted for disease, cell dose by graft source, Karnofsky score, and year of transplantation.
Grades II-IV acute GVHD were also adjusted for GVHD prophylaxis and year of transplantation, and were stratified by cell dose by graft source.
Grades III-IV acute GVHD was also adjusted for cell dose by graft source, GVHD prophylaxis, Karnofsky score, and year of transplantation.
Chronic GVHD was also adjusted for ATG use, Campath use, graft source, time from diagnosis to transplantation, recipient age by decade, and year of transplantation.
Graft failure was also adjusted for disease, GVHD prophylaxis, and conditioning regimen.
Baseline.